- Home
- SNGX vs NERV Comparison
SNGX vs NERV Comparison
Compare SNGX & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNGX
- NERV
- Stock Information
- Founded
- SNGX 1987
- NERV 2007
- Country
- SNGX United States
- NERV United States
- Employees
- SNGX N/A
- NERV N/A
- Industry
- SNGX Biotechnology: Pharmaceutical Preparations
- NERV Biotechnology: Pharmaceutical Preparations
- Sector
- SNGX Health Care
- NERV Health Care
- Exchange
- SNGX Nasdaq
- NERV Nasdaq
- Market Cap
- SNGX 10.1M
- NERV 12.0M
- IPO Year
- SNGX 1987
- NERV 2014
- Fundamental
- Price
- SNGX $2.86
- NERV $2.35
- Analyst Decision
- SNGX Strong Buy
- NERV Hold
- Analyst Count
- SNGX 1
- NERV 1
- Target Price
- SNGX $6.00
- NERV $5.00
- AVG Volume (30 Days)
- SNGX 10.2M
- NERV 41.4K
- Earning Date
- SNGX 11-07-2025
- NERV 11-04-2025
- Dividend Yield
- SNGX N/A
- NERV N/A
- EPS Growth
- SNGX N/A
- NERV N/A
- EPS
- SNGX N/A
- NERV 1.48
- Revenue
- SNGX N/A
- NERV N/A
- Revenue This Year
- SNGX N/A
- NERV N/A
- Revenue Next Year
- SNGX N/A
- NERV N/A
- P/E Ratio
- SNGX N/A
- NERV $1.58
- Revenue Growth
- SNGX N/A
- NERV N/A
- 52 Week Low
- SNGX $1.09
- NERV $1.15
- 52 Week High
- SNGX $6.23
- NERV $3.00
- Technical
- Relative Strength Index (RSI)
- SNGX 49.77
- NERV 59.22
- Support Level
- SNGX $2.72
- NERV $2.26
- Resistance Level
- SNGX $3.11
- NERV $2.47
- Average True Range (ATR)
- SNGX 0.49
- NERV 0.15
- MACD
- SNGX -0.10
- NERV -0.01
- Stochastic Oscillator
- SNGX 3.99
- NERV 36.71
About SNGX Soligenix Inc.
Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.